Image provided by Erik Orava and Dr. Jean Gariépy Image provided by Erik Orava and Dr. Jean Gariépy Image provided by Suji Thmmalingam Dr. David Hampson Image provided by Suji Thmmalingam Dr. David Hampson

Biotherapeutics Home

The Director of the Canadian Institutes of Health Research Training Program: Dr. David R. Hampson, Professor of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto. Please email Rob Reedijk for all inquiries

Widespread Evidence of GABAergic Changes in the Cerebellum, Limbic and Cortical Regions in the Autism Brain

Dr. Gene Blatt
Director of Neuroscience, Hussman Institute for Autism Research, Baltimore, Maryland
Friday, May 2, 2014 - 11:00am

Host: Dr. David Hampson

Pharmacy Building Room 850
Pharmacy seminar

One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering
and
Multiplex genome engineering using CRISPR/Cas systems

Dr. Feng Zhang

Department of Brain and Cognitive Sciences
Department of Biological Engineering
Massachusetts Institute of Technology
October 16, 2013 - 4:00pm
Host: Dr. Stephane Angers and Dr. David R. Hampson
Pharmacy Building Auditorium PB-B250
CIHR Biological Therapeutics Training Program Seminar


The Biological Therapeutics Training Program is proud to announce its sponsorship and participation in the 2013 Neurobiology Meeting, taking place at the University of Toronto in June, hosted by Dr. Oliver Ernst (Biochemistyr Department) and featuring a keynote address by Brian Kobilka, 2012 Nobel Laureate.

 



Biological Therapeutic Meetings, University of Toronto, May 2-3, 2013
In Spring 2013, the Biotherapeutics Program will hold two symposia on consecutive days on
1) The Blood Brain Barrier, and
2) Mechanisms of distribution of macromolecules and nanoparticle in tissues

Click here to view full program


  

 

Tumor-penetrating transport of cancer drugs is activated by the peptide iRGD (multicolored ring), which binds to integrin receptors (blue and yellow) in tumor blood vessels, and is subsequently cleaved. The cleaved peptide then binds to neuropilin-1 receptors (purple), activating a transport system that carries coadministered drugs, such as antibodies (green), deeper into tumor tissue.

Image: Peter Allen/University of California, Santa Barbara

Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs, Kazuki N. Sugahara, et al.

Science 328, 1031 (2010);

 

 

 

Theme by Danetsoft and Danang Probo Sayekti inspired by Maksimer